A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in ...

Disrupted sleep patterns in Alzheimer’s disease may be more than a symptom—they could be a driving force. Researchers at ...

When we think about dementia, we often think of a person experiencing memory loss and confusion. While it’s true that these ...

Two new studies suggest that chronic sleep problems may accelerate brain ageing and increase the risk of dementia ...

Intellia Therapeutics (NTLA) stock plummets after the company's Q3 updates indicate a patient deeath in a Phase 3 for its nex ...

Lowering the transcription factor PU.1 reprograms microglia into a neuroprotective, lymphoid-like state that compacts amyloid ...

New diagnostic kits aim to revolutionize early screening of the disease, potentially allowing patients to receive ...

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its ...

In a phase 1 trial, a gene-editing therapy that targets ANGPTL3 was associated with few serious adverse events and at higher ...

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

Microglia (green) responding to aggregated beta-amyloid plaques (blue) in the mouse cortex. (Credit: Jessica M. Crowley) A ...